Clinical trials
Chemoradiotherapy clinical trials
Below are recruiting chemoradiotherapy clinical trials, each written for real people, not researchers. We’re tracking 231 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06142760Recruiting
MRI-guided chemoradiation for cervical cancer
This trial uses MRI scans during chemoradiation to improve treatment accuracy for cervical cancer. It may help patients who need standard chemoradiation plus brachytherapy.
HeidelbergAges 18 years+ - NCT06102057RecruitingPhase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
DresdenAges 18 years+ - NCT06052332Recruiting
Comparing two pre-surgery treatments for older adults with rectal cancer
This study compares two approaches to treating rectal cancer in people age 70 and older who have not yet had surgery. One approach gives chemotherapy and radiation before surgery, and the other adds more chemotherapy after radiation. The goal is to find which plan works better with fewer side effects.
Antwerp, AntwerpenAges 70 years+ - NCT06048926Enrolling by invitation
Carrelizumab with chemoradiation for advanced esophageal cancer
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
NanjingAges 18–75 - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT05632809RecruitingPhase 2
Boosting immune cells after lung cancer chemoradiation
This trial studies whether a medicine called NKTR-255 can help restore and strengthen immune cells after standard chemoradiation for non-small cell lung cancer. The goal is to improve how well the body can fight the cancer after initial treatment.
Houston, TexasAges 18 years+ - NCT02297217RecruitingPhase 2
Chemoradiation for advanced esophagus cancer that can’t be cured
This trial studies whether a combination of chemotherapy and radiation can help people with advanced esophageal cancer who cannot have curative treatment. It focuses on people who are having swallowing trouble and may be able to start treatment soon.
Calgary, AlbertaAges 18 years+ - NCT05494190Recruiting
Treatment strategy for lymph node spread in hypopharyngeal cancer
This trial studies treatment choices for people with hypopharyngeal squamous cell cancer that has spread to certain neck lymph nodes. The goal is to help control the cancer in the neck and improve outcomes when the lymph node area can be surgically managed.
Harbin, HeilongjiangAges 18–75 - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT05340491RecruitingPhase 3
Radiation plus immunotherapy for repeat nasopharyngeal cancer
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Guangzhou, GuangdongAges 18–70 - NCT04815694Recruiting
MRI-guided radiotherapy for rectal cancer
This trial tests whether using MRI scans to guide radiotherapy can improve treatment for people with a certain type of rectal cancer. It focuses on patients whose tumors have not spread to other parts of the body and who have specific tumor features seen on MRI.
Roma, RomaAges 18 years+ - NCT04821778RecruitingPhase 3
Testing chemoradiotherapy for esophageal and stomach junction cancer
This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.
Anyang, HenanAges 18 years+ - NCT04765514RecruitingPhase 2
Chemo with radiation versus chemo alone for older brain tumor patients
This trial compares two standard treatments for newly diagnosed glioblastoma (a serious brain cancer) in older and frail patients: chemo plus radiation versus chemo alone. It may help determine which approach works best and is safest for people in your age and health group.
Calgary, AlbertaAges 65 years+ - NCT03907826RecruitingPhase 3
PD-1 therapy plus chemoradiation for recurrent nasopharyngeal cancer
This trial studies whether adding a PD-1 antibody (an immunotherapy) to standard chemoradiation can better control recurrent nasopharyngeal cancer that can’t be removed with surgery. If you qualify, you’d receive the study treatment and be closely monitored for side effects and cancer response.
Guangzhou, GuangdongAges 18–70 - NCT03694236RecruitingPhase 1/Phase 2
Durvalumab with chemoradiation before lung tumor surgery
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
Seoul, SeoulAges 20 years+
Hear when a new Chemoradiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chemoradiotherapy?
- Yes. Clin2 currently lists 231 recruiting chemoradiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chemoradiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chemoradiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.